1. Background
2. Objectives
3. Methods
3.1. Study Subjects and Design
3.2. Sample Preparation and Biochemical Examination
3.3. Serum Liver and Kidney Function Biomarkers
3.4. Measurement of Antioxidant Parameters
3.5. Serum Total Antioxidant Capacity (TAC)
3.6. Statistical Analysis
4. Results
| Groups | Parameter | ||
|---|---|---|---|
| Body Weight (g) | Liver (g) | Kidney (g) | |
| Group 1 | 238.2 ± 2.6A | 6.28 ± 2.9B | 4.5 ± 1.65A |
| Group 2 | 218.5 ± 2.8A | 8.33 ± 2.4A | 2.9 ± 1.49A |
| Group 3 | 232.7 ± 3.3A | 6.35 ± 4.9B | 4.1 ± 1.52A |
| Group 4 | 236.6 ± 2.9A | 6.77 ± 4.4B | 3.4 ± 1.63A |
aValues are presented as mean ± SE.
bLetters A and B in each column indicate significant differences at P ≤ 0.05.
| Groups | Parameter | |||
|---|---|---|---|---|
| AST (U.L-1) | ALT (U.L-1) | ALP (U.L-1) | Bilirubin (mg.dL-1) | |
| Group 1 | 161.3 ± 4.2B | 78.5 ± 3.6B | 445.3 ± 3.8B | 2.7 ± 0.32B |
| Group 2 | 367.5 ± 3.7A | 170.7 ± 4.9A | 895.1 ± 5.6A | 4.2 ± 0.94A |
| Group 3 | 170.7 ± 3.3B | 80.2 ± 2.3B | 482.6 ± 3.9B | 4.6 ± 0.34B |
| Group 4 | 155.3 ± 2.2B | 77.8 ± 5.5B | 455 ± 5.1B | 3.7 ± 0.29B |
aValues are presented as mean ± SE.
bLetters A and B in each column indicate significant differences at P ≤ 0.05.
| Groups | Parameter | |
|---|---|---|
| Creatinine (mg.dL-1) | Urea (mg.dL-1) | |
| Group 1 | 3.4 ± 0.87B | 26.2 ± 3.4B |
| Group 2 | 4.1 ± 3.11A | 55.4 ± 1.9A |
| Group 3 | 3.7 ± 0.98B | 25.7 ± 1.7B |
| Group 4 | 2.7 ± 0.79B | 27 ± 4.4B |
aValues are presented as mean ± SE.
bLetters A and B in each column indicate significant differences at P ≤ 0.05.
| Groups | Parameter | ||
|---|---|---|---|
| MDA (nmol.mL-1) | G-SH (µmol.mL-1) | TAC | |
| Group 1 | 487.4 ± 3.7B | 52.9 ± 5.5A | 579.8 ± 3.9A |
| Group 2 | 642.8 ± 3.3A | 29.3 ± 4.1B | 429.4 ± 3.1B |
| Group 3 | 498.5 ± 3.7B | 49.8 ± 4.3A | 524.5 ± 2.4A |
| Group 4 | 488.3 ± 6.1A | 55.1 ± 6.4A | 548.2 ± 4.3A |
aValues are presented as mean ± SE.
bLetters A and B in each column indicate significant differences at P ≤ 0.05.
4.1. Iron Oxide Concentration in Liver and Kidneys
| Groups | Parameter | |
|---|---|---|
| Kidneys | Liver | |
| Group 1 | 4.37 ± 4.1A | 6.23 ± 2.4A |
| Group 2 | 11.24 ± 2.8B | 14.8 ± 3.7B |
| Group 3 | 6.52 ± 3.4A | 7.98 ± 4.1A |
| Group 4 | 5.38 ± 4.9A | 6.14 ± 3.3A |
aValues are presented as mean ± SE.
bLetters A and B in each column indicate significant differences at P ≤ 0.05.
4.2. Effects of Histopathological Changes on Studied Organs
4.2.1. Kidneys
Light photomicrographs of the kidney. 1A, control group: normal renal glomeruli (star) (H&E, X100); 1B, proximal convoluted tubules (thin arrow), distal tubules (thick arrow) (H&E, X100); 1C, Iron oxide treated group: glomerular destruction and congestion (star) (H&E, X400); 1D, iron oxide treated group: showing hyaline casts (black arrow), in some tubules and some tubules with damaged epithelial cells (white arrow) (H&E, X400); 1E, Iron oxide+ S.platensis group: shows normal renal glomeruli and tubules, without any congestion or damaged cells (H&E, X100).
4.2.2. Liver
Light photomicrographs of the liver. 2A, control group: shows a central vein (black star) with hepatocyte arranged in cords. Cords of hepatocytes enclose blood sinusoids (white arrow) (H&E, X40). 2B, iron oxide treated group: some hepatocytes show dark nuclei and dense acidophilic cytoplasm (arrow) (H&E, X400). 2C, iron oxide treated group: dilated and congested central veins (arrow) (H&E, X400). 2D, iron oxide treated group: dilated sinusoids (arrow) (H&E, X400). 2E, iron oxide treated group: shows lymphocytic infiltration and mild inflammatory areas (arrows) (H&E, X400). 2F, iron oxide+ S.Platensis group: shows normal central vain without any congestion and ameliorated cords of hepatocytes enclose blood sinusoids (H&E, X40).

